Gba2 Gene Glucosylceramidase Beta 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GBA2 (Glucosylceramidase Beta 2) encodes a membrane-associated enzyme that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. It is also known as beta-glucosidase 2 or non-lysosomal glucosylceramidase.
| Property | Value |
|---|---|
| Gene Symbol | GBA2 |
| Full Name | Glucosylceramidase Beta 2 |
| Chromosomal Location | 9q34.2 |
| NCBI Gene ID | 57733 |
| Ensembl ID | ENSG00000143633 |
| UniProt ID | Q9HCG6 |
GBA2 (Glucosylceramidase Beta 2) is a non-lysosomal enzyme that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose. It plays a crucial role in glycosphingolipid metabolism, particularly in the final step of glucosylceramide catabolism outside the lysosome. Mutations in GBA2 cause autosomal recessive hereditary spastic paraplegia (SPG46) and are a significant risk factor for Parkinson's disease. The enzyme is expressed in various tissues including brain, liver, and testis.
GBA2 is a member of the glycoside hydrolase family 4. It is a bilayer membrane-associated enzyme localized primarily to the endoplasmic reticulum and plasma membrane. Unlike lysosomal glucocerebrosidase (GBA1), GBA2 functions in a non-lysosomal compartment and has distinct substrate specificity.
While GBA1 mutations are major risk factors for Parkinson's disease, GBA2 variants have also been associated with PD risk. Studies have shown:
GBA2 compensates for GBA1 deficiency:
The study of Gba2 Gene Glucosylceramidase Beta 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.